FDA grants breakthrough therapy designation to Omeros' MASP-2 inhibitor OMS721
Omeros announced the FDA has granted breakthrough therapy designation to OMS721 for treatment of patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy, specifically those patients who have persistent TMA despite modification of immunosuppressive therapy. April 26, 2018